News

Pursuant to its recent End of Phase II meeting with the U.S. Food & Drug Administration (FDA) Division of Pulmonary, Allergy and Rheumatology Products, Aurinia believes this Phase

The acquisition includes remetinostat, a skin-directed HDAC inhibitor, and birinapant, a bivalent SMAC mimetic, and all intellectual property and data associated with Tetralogic’s HDAC inhibitor and SMAC mimetic

The deal provides Knudra with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering of model organisms. ERS Genomics holds rights to the foundational

The trial will explore whether the use of the citrate anticoagulant extends the extracorporeal circuit life in acute kidney patients undergoing continuous renal replacement therapy (CRRT). The first

The drug is intended to be used in combination with letrozole as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-)

Allergan acquired Tobira for an upfront payment of $28.35 per share, in cash, and additional Contingent Value Rights (CVRs) that may be payable based on the successful completion

AndexXa is currently under EMA review for reversal of Factor Xa inhibition in patients experiencing a life-threatening or uncontrolled bleed and for patients requiring urgent or emergency surgery.

In April of this year, the companies announced an upfront payment from Gilead of $400m for the acquisition of Nimbus Apollo, and another potential $800m in development-related payments;

The new offering, IBM Watson for Patient Safety, will run on the Watson Health Cloud. The collaboration will combine Watson's cognitive computing ability with Celgene's deep history and experience